MX2020009859A - Linfocitos que expresan construcciones de direccionamiento heterologas. - Google Patents
Linfocitos que expresan construcciones de direccionamiento heterologas.Info
- Publication number
- MX2020009859A MX2020009859A MX2020009859A MX2020009859A MX2020009859A MX 2020009859 A MX2020009859 A MX 2020009859A MX 2020009859 A MX2020009859 A MX 2020009859A MX 2020009859 A MX2020009859 A MX 2020009859A MX 2020009859 A MX2020009859 A MX 2020009859A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- heterologous targeting
- expressing heterologous
- targeting constructs
- lymphocytes expressing
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title abstract 5
- 230000008685 targeting Effects 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 5
- 230000003213 activating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 210000004964 innate lymphoid cell Anatomy 0.000 abstract 1
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona linfocitos modificados por ingeniería genética (por ejemplo, linfocitos T ?d, linfocitos NK, linfocitos T tipo NK, células linfoides innatas modificadas por ingeniería genética o células MAIT) que comprenden una construcción de direccionamiento heteróloga que carece de un dominio de señalización intracelular capaz de activar el linfocito en el cual se exprese la construcción. Se proporcionan además composiciones de linfocitos modificados por ingeniería genética (por ejemplo, células T ?d) y métodos para usar los linfocitos modificados por ingeniería genética (por ejemplo, células T ?d, por ejemplo, una parte de una terapia de células T adoptivas).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1804701.9A GB201804701D0 (en) | 2018-03-23 | 2018-03-23 | Lymphocytes expressing heterologous targeting constructs |
PCT/EP2019/057469 WO2019180279A1 (en) | 2018-03-23 | 2019-03-25 | Lymphocytes expressing heterologous targeting constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020009859A true MX2020009859A (es) | 2021-02-16 |
Family
ID=62068083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020009859A MX2020009859A (es) | 2018-03-23 | 2019-03-25 | Linfocitos que expresan construcciones de direccionamiento heterologas. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210015867A1 (es) |
EP (2) | EP3768696A1 (es) |
JP (1) | JP2021519063A (es) |
KR (1) | KR20220029292A (es) |
CN (1) | CN112513067A (es) |
AU (1) | AU2019239705A1 (es) |
BR (1) | BR112020019143A2 (es) |
CA (1) | CA3094766A1 (es) |
EA (1) | EA202092261A1 (es) |
GB (1) | GB201804701D0 (es) |
IL (1) | IL277517A (es) |
MX (1) | MX2020009859A (es) |
PH (1) | PH12020551538A1 (es) |
WO (1) | WO2019180279A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
GB202013962D0 (en) | 2020-09-04 | 2020-10-21 | Gammadelta Therapeutics Ltd | Immunotherapy composition |
CN115381965B (zh) * | 2022-09-01 | 2023-03-14 | 广东龄值生物科技有限公司 | 一种γδT细胞功能化的磁性微球、制备方法及其用途 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
CA2507749C (en) | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
EP1638510B1 (en) | 2003-07-01 | 2015-09-02 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
JP4934426B2 (ja) | 2003-08-18 | 2012-05-16 | メディミューン,エルエルシー | 抗体のヒト化 |
CA2537055A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
EP1928506A4 (en) | 2005-08-19 | 2009-10-21 | Abbott Lab | IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF |
US8940707B2 (en) | 2010-10-28 | 2015-01-27 | Viropharma Incorporated | Maribavir isomers, compositions, methods of making and methods of using |
ES2643387T3 (es) | 2011-05-19 | 2017-11-22 | Instituto De Medicina Molecular | Estirpe celular de linfocitos que comprende células gama-delta, composición y método de producción de la misma |
GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
IL252131B2 (en) | 2014-11-17 | 2023-04-01 | Adicet Bio Inc | Transgenic gamma delta T cells |
GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
CN114958738A (zh) | 2015-06-09 | 2022-08-30 | 淋巴-淋巴细胞活化技术公司 | 用于生产TCRγδ+T细胞的方法 |
JP2018533373A (ja) | 2015-10-30 | 2018-11-15 | キャンサー・リサーチ・テクノロジー・リミテッド | 非造血組織常在性γδ T細胞の増幅および該細胞の使用 |
SG11201803493UA (en) * | 2015-11-27 | 2018-05-30 | Cartherics Pty Ltd | Genetically modified cells and uses thereof |
US20220025001A1 (en) * | 2016-04-28 | 2022-01-27 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
MX2018013864A (es) | 2016-05-12 | 2019-06-10 | Adicet Bio Inc | Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas. |
CN109844099B (zh) * | 2016-07-25 | 2024-01-02 | 美国政府(由卫生和人类服务部的部长所代表) | 产生经修饰的自然杀伤细胞的方法及使用方法 |
GB201707048D0 (en) | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
-
2018
- 2018-03-23 GB GBGB1804701.9A patent/GB201804701D0/en not_active Ceased
-
2019
- 2019-03-25 JP JP2020551300A patent/JP2021519063A/ja active Pending
- 2019-03-25 EP EP19713774.8A patent/EP3768696A1/en active Pending
- 2019-03-25 MX MX2020009859A patent/MX2020009859A/es unknown
- 2019-03-25 AU AU2019239705A patent/AU2019239705A1/en active Pending
- 2019-03-25 KR KR1020207030413A patent/KR20220029292A/ko active Search and Examination
- 2019-03-25 CA CA3094766A patent/CA3094766A1/en active Pending
- 2019-03-25 WO PCT/EP2019/057469 patent/WO2019180279A1/en unknown
- 2019-03-25 CN CN201980034162.8A patent/CN112513067A/zh active Pending
- 2019-03-25 BR BR112020019143-4A patent/BR112020019143A2/pt unknown
- 2019-03-25 US US17/040,917 patent/US20210015867A1/en active Pending
- 2019-03-25 EA EA202092261A patent/EA202092261A1/ru unknown
- 2019-03-25 EP EP21194817.9A patent/EP4015525A3/en active Pending
-
2020
- 2020-09-22 IL IL277517A patent/IL277517A/en unknown
- 2020-09-23 PH PH12020551538A patent/PH12020551538A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220029292A (ko) | 2022-03-08 |
EP4015525A3 (en) | 2023-04-26 |
EP4015525A2 (en) | 2022-06-22 |
IL277517A (en) | 2020-11-30 |
EA202092261A1 (ru) | 2021-03-05 |
CN112513067A (zh) | 2021-03-16 |
CA3094766A1 (en) | 2019-09-26 |
PH12020551538A1 (en) | 2021-06-07 |
WO2019180279A1 (en) | 2019-09-26 |
AU2019239705A1 (en) | 2020-11-05 |
BR112020019143A2 (pt) | 2021-01-05 |
US20210015867A1 (en) | 2021-01-21 |
GB201804701D0 (en) | 2018-05-09 |
EP3768696A1 (en) | 2021-01-27 |
JP2021519063A (ja) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551538A1 (en) | Lymphocytes expressing heterologous targeting constructs | |
MX2020006688A (es) | Celulas presentadoras de antigenos artificiales y metodos de uso. | |
WO2019090003A9 (en) | Chimeric antigen receptors specific for b-cell maturation antigen (bcma) | |
MX2021009742A (es) | Celulas asesinas naturales (nk) modificadas para inmunoterapia. | |
NZ765695A (en) | Immune cell organoid co-cultures | |
AR122050A2 (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
MX2020008542A (es) | Composiciones y métodos para el suministro de proteínas membranales. | |
MX2019006374A (es) | Receptores inmunes sinteticos y metodos de usos de ellos. | |
MX2020013977A (es) | Proteínas quiméricas transmembrana y usos de las mismas. | |
MX2021008142A (es) | Metodos para cosechar cultivos de celulas de mamifero. | |
MX2023007496A (es) | Antifolatos poliglutamados y sus usos. | |
MX2017004890A (es) | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. | |
MY195733A (en) | Compositions and Methods for Immunotherapy | |
MX2017005344A (es) | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. | |
WO2018081648A8 (en) | ANTI-MIC ANTIBODIES AND METHODS OF USE | |
AU2017241807A1 (en) | Medium, methods, cells and secreted factors for stem cell culture and therapy | |
AU2016335217A8 (en) | Antigen receptors and uses thereof | |
MX2017008737A (es) | Poblaciones de celulas rpe y metodos para generar las mismas. | |
MX2019013151A (es) | Composiciones y metodos para expresar otoferlina. | |
MX2019012360A (es) | Composiciones y metodos mejorados de celulas t. | |
MX2020003483A (es) | Composiciones de pienso para animales mejoradas y metodos de uso. | |
AU2018276117A1 (en) | Animal feed supplement | |
SG10201907249WA (en) | Human cytomegalovirus comprising exogenous antigens | |
WO2018115973A3 (en) | INTRACELLULAR ADMINISTRATION WITHOUT REVERSIBLE PERMEABILIZATION VECTOR | |
MX2022011700A (es) | Recipientes de microingredientes solubles y metodos para preparar piensos para animales usando los recipientes. |